C Rad EV/FCF
The EV/FCF (Enterprise Value to Free Cash Flow) of C Rad (CRAD B.ST) as of Jul 27, 2026 is 10.90. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 34.09 — a change of -68.01% (lower).
Get this data via API
Financial Data API
EV/FCF
10.90
YoY
-68.01%
Last updated:
EV/FCF (Enterprise Value to Free Cash Flow) of C Rad is 2026 10.90 . EV/FCF (Enterprise Value to Free Cash Flow) of C Rad was 2025 34.09 . It decreases by -68.01% lower compared to the previous year.
Access this data via the Eulerpool API
C Rad Stock analysis
What does C Rad do? The company C Rad AB is a Swedish company based in Uppsala, founded in 1989. The company specializes in the development and production of products for medical imaging, particularly for radiology. Since its founding, the company has become a global provider of innovative solutions for radiology and nuclear medicine.
The main goal of C Rad AB is to improve patient care and workflow in radiology by offering solutions that increase treatment efficiency and quality. C Rad's products are tailored to the needs of radiologists, technicians, and patients, aiming to make operation simple and intuitive.
The company offers a wide range of products divided into various categories. One of the main categories is computed tomography (CT), for which C Rad has developed a range of accessories. These accessories aim to improve the image quality of CT scans and reduce the dose of ionizing radiation for patients and medical personnel. An example of such an accessory is a special software for analyzing lung images, which works in real time and enables radiologists to make quick and accurate diagnoses.
Another important category for C Rad is magnetic resonance imaging (MRI). Here, the company offers a range of products that adapt to the needs of radiologists and patients. One such solution is magnetic muscle stimulation. This technology uses strong magnetic fields to stimulate patients' muscles, thereby positioning the body for better imaging. This type of solution is particularly useful for patients with limited mobility or individuals who have difficulty remaining still due to pain or discomfort.
C Rad also develops products for radiation therapy. Here, the focus is on solutions that help control and reduce radiation dose for patients and medical personnel. Examples include dosimeters that measure radiation dose and allow technicians to accurately determine the radiation dose for each patient.
In addition to accessories for medical imaging, C Rad also offers a wide range of software solutions. One such solution is Radimetrics software. This software uses machine learning technologies and provides real-time guidance to doctors and technicians on how to optimize workflow and reduce radiation dose for patients.
Another example of C Rad's software solutions is dosimetry software. This solution allows technicians to monitor and control radiation dose and image quality in real time. Such software is particularly useful for monitoring radiation dose in radiation therapy and medical imaging.
In conclusion, C Rad AB is a company characterized by innovation and quality. Through the continuous development of new solutions, they aim to improve the lives of patients and medical personnel and increase the efficiency and quality of radiology. C Rad is one of the most popular companies on Eulerpool.
Frequently Asked Questions about C Rad stock
EV/FCF (Enterprise Value to Free Cash Flow) of C Rad is 10.90 in 2026.
Access this data via the Eulerpool API
Valuation — C Rad
All Key Metrics — C Rad
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth